News

The drug candidate ELND-005/AZD-103 has undergone Phase I clinical trials and appears to be safe and well tolerated at all doses and dosing regimes examined in approximately 110

The biopharmaceutical company expects to eliminate 14 positions including executive and non-executive employees in all areas of operations. All clinical development staff will remain with the company. Tapestry

Research teams at the Imperial College of London, in collaboration with the UK-based MDEX Consortium will conduct the trial of AVI-4658 for AVI in the UK. The proof-of-principle

Nearly 1300 epilepsy patients, aged between 16 and 70 years, will take part in three trials. Two studies are designed to evaluate the efficacy and safety of brivaracetam

Ronald Zarrella, chairman and CEO of Bausch & Lomb, said: “With a strong and supportive partner in Warburg Pincus, we are well-positioned to create new opportunities for Bausch

The company will launch its product immediately under the tradename TriLegest Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets). The company’s generic oral contraceptive

CHDI’s funding builds upon an earlier successful collaboration between Isis and CHDI, in which CHDI provided Isis with funding for studies that demonstrated the feasibility of using antisense

According to the researchers: “Treatment with thymosin beta 4 resulted in increased re-epithelialization and considerable capillary in-growth. Vessel counts showed a significant increase in the number of vessels

The main objective of this trial is to evaluate the analgesic efficacy of nalbuphine extended release (ER). There are approximately 135 patients with chronic pain secondary to osteoarthritis